Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
Go back to Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)| (NASDAQ: ACRS) | Delayed: 4.92 +0.08 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.84 | 52 Week High | $33.88 | |||
| Open | $4.77 | 52 Week Low | $14.12 | |||
| Day High | $5.12 | P/E | N/A | |||
| Day Low | $4.77 | EPS | $0.00 | |||
| Volume | 1,865,406 | |||||
